PharmaVoice 100: Page 3

  • A portrait of Dr. Jula Inrig framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Jula Inrig
    Image attribution tooltip
    Profile // PharmaVoice 100

    Innovators: Dr. Jula Inrig

    The longtime devotee to kidney disease research is using a novel trial design to advance treatments for rare conditions at Travere.

    By • Sept. 6, 2022
  • A portrait of Dr. Michael Hayden framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Michael Hayden
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Dr. Michael Hayden

    The CEO at Prilenia has an unwavering dedication to address the needs of HD patients and their families.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Pam Diamond framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Pam Diamond
    Image attribution tooltip
    Profile // PharmaVoice 100

    DE&I Champions: Dr. Pam Diamond

    The chief medical officer and co-founder of Curavit Clinical Research is bringing a new level of inclusiveness to clinical trials.

    By • Sept. 6, 2022
  • A portrait of Samantha Du framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Samantha Du
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Samantha Du

    The CEO of Zai Lab is at the forefront of the movement to boost innovation in China’s biotech sector while delivering needed solutions to patients around the world.

    By • Sept. 6, 2022
  • A portrait of Dr. Edward Kaye framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Edward Kaye
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Dr. Edward Kaye

    The CEO behind the first genetic therapy for Duchenne muscular dystrophy is looking to extend his winning streak at Stoke.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Elisha Hughes framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Elisha Hughes
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Elisha Hughes

    The director of research biostatistics at Myriad Genetics is looking to stretch the boundaries of science and change how breast cancer is detected in diverse patient populations.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Fahti Khosrowshahi framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Fahti Khosrowshahi
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Fahti Khosrowshahi

    The president, CEO and founder of Ceek Women’s Health is on a mission to upend the OBGYN market.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Faraz Ali framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by NASDAQ
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Faraz Ali

    The CEO is leading Tenaya Therapeutics forward in ways that combine people-focused leadership, a strong dedication to patients and bold ideas for the future.

    By Alexandra Pecci • Sept. 6, 2022
  • A portrait of Frank Lee framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Frank Lee
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Frank Lee

    At Forma Therapeutics, the CEO and president is placing patients in leadership roles to weave patient centricity into the company’s business and development model.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Giacomo Chiesi framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Giacomo Chiesi
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Giacomo Chiesi

    For the head of Chiesi Global Rare Diseases, patient centricity is in his DNA.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Helen Sabzevari framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Helen Sabzevari
    Image attribution tooltip
    Profile // PharmaVoice 100

    Tech Wizards: Helen Sabzevari

    The CEO of Precigen is on a mission to develop next-generation gene and cell therapies for cancers, autoimmune disorders and more.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Helen Thackray framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Helen Thackray
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Dr. Helen Thackray

    The chief research and development officer at BioCryst Pharmaceuticals is leaning into decades of experience to advance a promising pipeline of rare disease products.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Henrietta Ukwu framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Henrietta Ukwu
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Dr. Henrietta Ukwu

    Novavax’s regulatory head helped the company pull off its first approvals with the FDA and the EMA — but her accomplishments in pharma run deep.

    By • Sept. 6, 2022
  • A portrait of Houda Hachad framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Houda Hachad
    Image attribution tooltip
    Profile // PharmaVoice 100

    Tech Wizards: Houda Hachad

    This inventor and 'entrepreneurial scientist' is developing new technologies to manage data and use insights from genomic testing at AccessDx Laboratory.

    By Alexandra Pecci • Sept. 6, 2022
  • A portrait of Dr. Ian Walters framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Ian Walters
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Dr. Ian Walters

    How the CEO of Portage Biotech is steering cancer R&D in a new direction by advancing diverse drug platforms.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Jane Barlow framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Jane Barlow
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Dr. Jane Barlow

    The executive vice president and chief clinical officer of Real Endpoints is boosting patient access to innovative therapies through value-based payer agreements.

    By • Sept. 6, 2022
  • A portrait of Jeanne Magram framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Jeanne Magram
    Image attribution tooltip
    Profile // PharmaVoice 100

    Innovators: Jeanne Magram

    Celsius Therapeutics’ CSO is turning ideas into approved medicines for patients with cancer and autoimmune diseases.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Jeff Fischer framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Jeff Fischer
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Jeff Fischer

    The co-founder and president led Longhorn Vaccines and Diagnostics to an unprecedented surge in production of its testing tech at the height of COVID-19 and is now pursuing a universal flu vaccine.

    By Karissa Waddick • Sept. 6, 2022
  • A portrait of Jennifer Gottlieb framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Jennifer Gottlieb
    Image attribution tooltip
    Profile // PharmaVoice 100

    DE&I Champions: Jennifer Gottlieb

    The global president and chief client officer of Real Chemistry is dedicated to ensuring all voices at the agency are heard and everyone has a seat at the table.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Jennifer Gould framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Jennifer Gould
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Jennifer Gould

    How the director of marketing excellence at GSK is helping usher in a new era of pharma marketing and patient personalization with a collaborative cross-industry approach.

    By Karissa Waddick • Sept. 6, 2022
  • A portrait of Jennifer Kelly framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Jennifer Kelly
    Image attribution tooltip
    Profile // PharmaVoice 100

    Tech Wizards: Jennifer Kelly

    The president of patient experience is helping transform clinical trials with an innovative platform.

    By • Sept. 6, 2022
  • A portrait of Dr. Jeremy Levin framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Jeremy Levin
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Dr. Jeremy Levin

    Over his 30-year career, the founder, chairman and CEO of Ovid Therapeutics has demonstrated that he is a patient advocate, scientist, clinician and innovator at heart.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Jim Anthony framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Jim Anthony
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Jim Anthony

    With a ready-for-anything attitude and a knack for relationship-building, the executive vice president and global head of Parexel Biotech is growing the CRO with a patient-first approach.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Jim Doherty framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Jim Doherty
    Image attribution tooltip
    Profile // PharmaVoice 100

    Innovators: Jim Doherty

    Sage Therapeutics’ chief development officer is leveraging innovative development strategies to create success against hard-to-treat brain disorders.

    By • Sept. 6, 2022
  • A portrait of John Oyler framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by John Oyler
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: John Oyler

    The CEO of BeiGene is using innovative business strategies to help the oncology biotech quickly hit new heights.

    By • Sept. 6, 2022